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“Mismatch can be considered to be present when the effective prosthetic valve area,
after insertion into the patient, is less than that of a normal human valve. . .occasion-
ally it can be a severe problem because the patient may be hemodynamically and
symptomatically worse after valve replacement.”
This is the definition of prosthesis-patient mismatch framed by Ra-himtoola1 when he coined the term in 1978. Rahimtoola suggestedthat the degree of prosthesis-patient mismatch could be quantifiedand that such quantification might aid in identifying patients at riskof clinical sequelae caused by this condition. DeCarlo and col-leagues2 seek to undertake these tasks in their report on small-sized
Sorin Bicarbon prostheses (Sorin Biomedica, Saluggia, Italy). Although seemingly
straightforward, application of Rahimtoola’s definition requires examination and
clarification of several complex concepts, including (1) measurement of prosthesis
size, (2) measurement of patient size, (3) normalization of these values, (4) selection
of referent values, and (5) assessment of the influence of prosthesis-patient size on
clinical outcome.
Prosthesis Size
Prosthesis size can be based on either geometric dimensions or functional perfor-
mance of the prosthesis (Table 1). Geometric expressions of prosthesis size include
labeled size and internal orifice size. Functional expressions of prosthesis size
include both in vitro and in vivo effective orifice area (EOA).
Although used frequently to assess the effect of prosthesis size on outcome,
labeled valve size is limited in this regard.3 Manufacturer’s labeled size refers
inconsistently to diameter of the external sewing ring (mechanical prostheses),
mounting ring (stented xenografts), or internal orifice (allografts and some stentless
xenografts). Furthermore, valves of the same type (mechanical or bioprosthetic) and
same labeled size from 2 different manufacturers nearly always have disparate
geometric dimensions.3 Given these limitations, labeled valve size is a poor choice
for analyzing the effect of prosthesis size on patient outcome. Recently, the
International Organization for Standardization (ISO) addressed these concerns by
recommending that manufacturers adopt a common standard for labeled prosthesis
size.4 The ISO suggested that labeled prosthesis size should represent the tissue
annulus diameter of the patient in whom the valve is to be implanted. However, it
represents an external dimension of a prosthesis and not the internal orifice through
which blood flows.
Unlike labeled prosthesis size or the ISO proposal, internal orifice size is a
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dimension directly related to blood flow and is a fixed and
reproducible geometric value obtained before valve inser-
tion. Internal orifice size might be expressed as the internal
diameter or the internal area, with the latter calculated by
assuming a circular shape and disregarding hinge areas of
mechanical valves and irregularities in bioprostheses; these
features represent limitations in the use of internal orifice
area to represent prosthesis size.
In vitro EOA is a functional determination of valve size.
It varies considerably, depending on conditions and tech-
niques of measurement and the type of prosthesis. In vitro
EOA can be determined under static hydrodynamic condi-
tions at a variety of flow rates or, alternatively, under
dynamic conditions with variable pulsatile waveforms and
flow rates. Artificial static EOA measurements performed
under steady flow are poorly reproduced from laboratory to
laboratory. Estimates of static EOA for bioprostheses vary
by as much as 100% as the steady flow rate increases.
Dynamic (pulsatile) in vitro EOA data are nonstandardized,
unreproducible, and unavailable. For these reasons, in vitro
EOA is generally unsuitable for assessment of the clinical
effect of prosthesis size.
In vivo EOA has been used extensively to examine the
relationship of prosthesis size, patient size, and clinical
outcome.5 Obtained by means of echocardiography after
implantation, in vivo EOA can be measured serially. In vivo
EOA is calculated from the continuity equation:
Aortic valve area (Alvot  VTIlvot)/VTItransvalvular
where Alvot is the area of the left ventricular outflow tract
(LVOT) just before the valve, VTIlvot is the velocity-time
integral of the pulsed Doppler velocity at the outflow tract
level, and VTItransvalvular is calculated from the continuous
wave Doppler velocity through the prosthetic valve.
The area obtained with this equation is the EOA, which
is smaller than the anatomic area and corresponds to the
smallest area of the jet as it exits the valve (vena contracta).
The shape of the inlet and the size of the orifice affect the
ratio between the anatomic orifice area and the EOA (coef-
ficient of orifice contraction).6 The continuity equation as-
sumes that flow coming into the narrowed orifice has a flat
profile; the actual flow profile varies between prostheses,
with mechanical prostheses having the greatest variance
from a flat profile.
A functional determination of prosthesis size, in vivo
EOA might vary widely, depending on a number of factors
related to measurement technique and patient state. Vari-
ability can be introduced in the measurement of the LVOT
diameter or the velocity at the outflow tract.7 In vivo EOA
values for bileaflet valves might be underestimated when
evaluated by means of echocardiography because of local-
ized high-velocity jets. Poor echocardiographic windows
and suboptimal Doppler recordings with improper align-
ment of the Doppler scan with the direction of flow might
also affect the accuracy of the method.
Although this method is, in theory, independent of flow,
flow dependency does exist.8 Most important, in vivo EOA
varies considerably with the state of the patient.8,9 In vivo
EOA might change from moment to moment with patient
activity, cardiac output and blood pressure, and dynamics of
the LVOT, as well as intrinsic prosthesis properties. Esti-
mates of bioprosthesis in vivo EOA are particularly sensi-
tive to the level of patient activity (rest vs exercise), with
measured in vivo EOA tending to increase with exercise.10
In vivo EOA values have been observed to change during
the first year after implantation as hemodynamic data
change.11,12
Patient Size
Assessment of the effect of aortic prosthesis size on out-
come should take into account the size of the patient. Patient
size has been quantified on the basis of height, weight, and
body surface area (BSA). In the contemporary literature
most studies use BSA, and there is growing agreement that
this is the most suitable measurement in this regard.
Normalization
Normalization of any expression of prosthesis size can be
made to body size. This concept is used to account for both
prosthesis size and patient size and, furthermore, to compare
values in individual patients with those in the larger popu-
lation. When BSA is used to express patient size, 2 common
normalization methods are used to express the relationship
between prosthesis and patient size: indexing and standard-
ization.
An indexed valve dimension is obtained by dividing that
dimension by the BSA. Any valve dimension, whether
geometric or functional, can be indexed. For example, both
the geometric internal prosthesis area and the in vivo EOA
might be expressed as indexed values (ie, square centimeter
per square meter of BSA).
The concept of standardization enables comparison of
individual patient values with those obtained from a popu-
lation. Use of dimensionless standardized values is based on
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the fact that native annulus size exhibits considerable vari-
ability among normal individuals of any given size. Rimoldi
and Lev13 introduced the idea that normality and abnormal-
ity could be expressed in quantitative terms as the number
of SDs away from normal size a given patient’s cardiac
structures measure. This is the concept of the Z value.
In the current context Z is the number of SDs between
the patient’s prosthetic aortic valve size and the mean nor-
mal native aortic valve size for a patient of a given BSA.
Capps and colleagues14 have provided the reference values
for the distribution of native aortic valve diameters in the
general population. By means of these data and measured
prosthetic internal orifice diameters, the standardized orifice
size, or Z value, might be determined for any patient re-
ceiving a prosthetic aortic valve.
These concepts of normalization enable expression of
prosthesis-patient size. Prosthesis-patient size is a means of
quantifying the relationship between prosthesis size and
patient size. As stated above, any term representing pros-
thesis size (in vivo EOA or internal orifice area) can be
indexed to patient BSA. Furthermore, prosthesis-patient
size might be related to mean values in the general popu-
lation by means of standardization (the Z value). There is an
approximately logarithmic relationship between indexed
and standardized prosthesis-patient size (Figure 1).
Referent Values
There is interest in providing referent values for prosthesis-
patient size to aid surgeons in prosthesis selection, such that
each patient receives a prosthesis of sufficient size. De Carlo
and colleagues2 seek to accomplish this task for the Sorin
Bicarbon prosthesis. In theory referent values could be
generated from both geometric and functional measures of
prosthesis size. Although they do not address directly the
function of a prosthesis in a given patient, referent values on
the basis of geometric measures of prosthesis size are de-
termined before implantation, have little variability, and are
independent of hemodynamic state. Pibarot and col-
leagues15 have suggested that rather than using a geometric
prosthesis dimension as a fixed reference for prosthesis size,
a fixed referent value of in vivo EOA should be used. They
termed this “projected EOA.” Such referent values were
obtained from informal meta-analysis of literature sources.
This strategy has several important drawbacks: it suffers
from flow dependency, a large scatter in the data, rest versus
exercise differences, and limited availability of data for each
prosthesis size and model. Thus referent values on the basis
of geometric determinants of prosthesis size are preferable
at this time.
Prosthesis-Patient Size and Clinical Outcome
Given the broad definition of prosthesis-patient mismatch
and the methodology for determination of prosthesis-patient
size, what is the clinical importance of these concepts?
Among cardiac surgeons and cardiologists, there is consid-
erable interest in aortic prosthesis size, with the common
notion being that placement of a relatively small valve
might jeopardize outcome. The reasoning behind the notion
that bigger valves are better seems logical.1,5 A larger pros-
thetic aortic valve will have superior hemodynamic perfor-
mance, which is manifested by lower transvalvular gradi-
ents. This should result in decreased left ventricular work
and more rapid and complete regression of left ventricular
hypertrophy. These factors, in turn, are purported to im-
prove clinical status and prolong survival. Although sup-
Figure 1. Indexed orifice area versus Z value for the aortic valve. The relationship is approximately logarithmic.
Gillinov, Blackstone, Rodriguez Editorials







porting data are limited, these statements have been ac-
cepted as fact.
Until recently, the effect of prosthesis-patient size on
survival was controversial. Although some studies sug-
gested that smaller prosthesis-patient size jeopardized early
or late survival,16 others did not support this finding.17,18
Recently, 3 large studies, each containing more than 1000
patients, have helped to clarify the effect of prosthesis-
patient size on survival. In a study of 1129 patients,
Hanayama and colleagues19 found that prosthesis-patient
size did not influence survival, New York Heart functional
class, or left ventricular mass index. Rao and associates20
examined a cohort of 2981 patients undergoing aortic valve
replacement; they observed that smaller prosthesis-patient
size was associated with greater operative mortality but did
not affect overall 12-year survival.
The question of prosthesis-patient size and mortality
after aortic valve replacement was addressed by Blackstone
and coworkers.21 In this study, including data on 13,258
aortic valve replacements from 9 data sources, 30-day mor-
tality increased 1% to 2% when indexed orifice area de-
creased to less than 1.2 cm2/m2 or standardized orifice size
decreased to less than 2.5 Z. However, no expression of
prosthesis-patient size was associated with reduced interme-
diate-term (0.5-5 years) or late-term (5-15 years) survival.
In contrast, patient risk factors, such as age, had a profound
effect on survival.
Although small prosthesis-patient size has a small effect
on operative mortality and no important effect on late sur-
vival, this does not rule out a possible influence on other
indices of clinical outcome. It is possible that highly active
and larger individuals might benefit from superior hemody-
namics that might be associated with greater prosthesis-
patient size. This assertion is very difficult to prove. Large
studies addressing this issue are warranted.
Aortic valve replacement improves survival in patients
with severe aortic stenosis. Assessment of the effect of
prosthesis-patient size in such patients requires adoption of
standard methodology. Indexed orifice area and standard-
ized orifice size depend on geometric measurements ob-
tained before implantation, are reproducible, and allow
comparison with the normal population. This is a preferred
method for assessing prosthesis-patient size. Indexed in
vivo EOA, a functional measurement obtained in an indi-
vidual patient in a given hemodynamic state, provides com-
plementary information. Future studies of the effect of pros-
thesis-patient size should, where possible, include both
types of measurement. Such a strategy will enable more
complete characterization of the effect of prosthesis-patient
size on clinical outcome.
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